Regeneron (REGN) Stock Forecast & Price Target

Q: What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron’s 12-month average price target is 774.10.

Q: What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron has 0.80% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is REGN a Buy, Sell or Hold?

Regeneron has a consensus rating of Moderate Buy which is based on 16 buy ratings, 6 hold ratings and 1 sell ratings.

Q: What is Regeneron’s price target?

The average price target for Regeneron is 774.10. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $1,057.00 ,the lowest forecast is $627.00. The average price target represents 0.80% Increase from the current price of $767.96.

Q: What do analysts say about Regeneron?

Regeneron’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

Q: How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

5,081 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Moderate Buy

16 Buy

6 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$774.10

▲(0.80% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $774.10 with a high forecast of $1,057.00 and a low forecast of $627.00. The average price target represents a 0.80% change from the last price of $767.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"488":"$488","773":"$773","1058":"$1,058","630.5":"$630.5","915.5":"$915.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1057,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.06K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":774.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$774.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$627.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[488,630.5,773,915.5,1058],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,750.11,773.7169230769231,797.3238461538461,820.9307692307692,844.5376923076923,868.1446153846153,891.7515384615385,915.3584615384616,938.9653846153847,962.5723076923077,986.1792307692308,1009.7861538461539,1033.393076923077,{"y":1057,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,750.11,751.9553846153847,753.8007692307692,755.6461538461539,757.4915384615384,759.3369230769231,761.1823076923077,763.0276923076923,764.873076923077,766.7184615384616,768.5638461538462,770.4092307692308,772.2546153846154,{"y":774.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,750.11,740.64,731.17,721.7,712.23,702.76,693.29,683.82,674.35,664.88,655.41,645.94,636.47,{"y":627,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":758.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":708.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":669.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":695.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":614.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":587.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":489.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":533.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":557.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":577.18,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":599.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":750.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$1,057

Average Price Target$774.10

Lowest Price Target$627.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Terence Flynn

Morgan Stanley

$767→$768

Hold

<0.01%

Upside

Reiterated

12/12/25

Morgan Stanley Reaffirms Their Hold Rating on Regeneron (REGN)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), Regeneron (NASDAQ: REGN) and Elicio Therapeutics (NASDAQ: ELTX)

Evan Seigerman

BMO Capital

$850

Buy

10.68%

Upside

Reiterated

12/11/25

Regeneron (REGN) Receives a Buy from BMO CapitalBreaking Down BCMA: Regeneron’s Post–ASH Call Highlights Its Linvo Strategy

Louise Chen

Scotiabank

$770

Hold

0.27%

Upside

Reiterated

12/11/25

Regeneron (REGN) Gets a Hold from Scotiabank

Mohit Bansal

Wells Fargo

$700→$745

Hold

-2.99%

Downside

Reiterated

12/10/25

Wells Fargo Keeps Their Hold Rating on Regeneron (REGN)

Salveen Richter

Goldman Sachs

$785→$788

Buy

2.61%

Upside

Reiterated

12/10/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Regeneron (NASDAQ: REGN)

Yifeng Liu

HSBC

$890→$985

Buy

28.26%

Upside

Reiterated

12/10/25

Regeneron price target raised to $985 from $890 at HSBCRegeneron price target raised to $985 from $890 at HSBC

Brian Abrahams

RBC Capital

$708

Hold

-7.81%

Downside

Reiterated

12/09/25

RBC Capital Sticks to Its Hold Rating for Regeneron (REGN)

John Newman

Canaccord Genuity

$850→$1,057

Buy

37.64%

Upside

Reiterated

12/04/25

Regeneron price target raised to $1,057 from $850 at CanaccordRegeneron price target raised to $1,057 from $850 at Canaccord

William Pickering

Bernstein

$818

Buy

6.52%

Upside

Reiterated

12/01/25

Bernstein Remains a Buy on Regeneron (REGN)

Cory Kasimov

Evercore ISI

$750

Buy

-2.34%

Downside

Reiterated

11/20/25

Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN)

Geoff Meacham

Citi

$700

Buy

-8.85%

Downside

Reiterated

11/19/25

Regeneron: Strategic Positioning and Growth Potential with Eylea-HD ApprovalWe see the approvals as a positive catalyst for the Eylea franchise, enabling it to more effectively contend with the competitive anti-VEGF market. Indeed, while PFS approval is still pending, immediate impact of these approvals could drive an inflection in Eylea-HD’s performance as early as 1Q26, helping counteract prevailing headwinds (competitive dynamics, loss of funding resulting in branded market share loss, and additional biosimilars launch). Over the long term, we project the anti-VEGF market to segment into distinct niches, with Eylea-HD competing with Vabysmo and capture significant share (20-25%) of the total market. We currently model 2026/2030 Eylea-HD sales of ($2.0B/$3.2B) and combined Eylea franchise sales of ($3.8B/$3.6B). Maintain Buy, TP $700.

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

11/19/25

Positive Outlook for Regeneron: Buy Rating Supported by Eylea HD Approval and Strong Portfolio

Carter Gould

Cantor Fitzgerald

$740

Buy

-3.64%

Downside

Reiterated

11/19/25

Cantor Fitzgerald Remains a Buy on Regeneron (REGN)

Trung Huynh

UBS

$595→$660

Hold

-14.06%

Downside

Reiterated

11/07/25

Regeneron price target raised to $660 from $595 at UBSRegeneron price target raised to $660 from $595 at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Terence Flynn

Morgan Stanley

$767→$768

Hold

<0.01%

Upside

Reiterated

12/12/25

Morgan Stanley Reaffirms Their Hold Rating on Regeneron (REGN)

Gregory Renza

Truist Financial

―

Buy

―

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (NASDAQ: CNTA), Regeneron (NASDAQ: REGN) and Elicio Therapeutics (NASDAQ: ELTX)

Evan Seigerman

BMO Capital

$850

Buy

10.68%

Upside

Reiterated

12/11/25

Regeneron (REGN) Receives a Buy from BMO CapitalBreaking Down BCMA: Regeneron’s Post–ASH Call Highlights Its Linvo Strategy

Louise Chen

Scotiabank

$770

Hold

0.27%

Upside

Reiterated

12/11/25

Regeneron (REGN) Gets a Hold from Scotiabank

Mohit Bansal

Wells Fargo

$700→$745

Hold

-2.99%

Downside

Reiterated

12/10/25

Wells Fargo Keeps Their Hold Rating on Regeneron (REGN)

Salveen Richter

Goldman Sachs

$785→$788

Buy

2.61%

Upside

Reiterated

12/10/25

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Regeneron (NASDAQ: REGN)

Yifeng Liu

HSBC

$890→$985

Buy

28.26%

Upside

Reiterated

12/10/25

Regeneron price target raised to $985 from $890 at HSBCRegeneron price target raised to $985 from $890 at HSBC

Brian Abrahams

RBC Capital

$708

Hold

-7.81%

Downside

Reiterated

12/09/25

RBC Capital Sticks to Its Hold Rating for Regeneron (REGN)

John Newman

Canaccord Genuity

$850→$1,057

Buy

37.64%

Upside

Reiterated

12/04/25

Regeneron price target raised to $1,057 from $850 at CanaccordRegeneron price target raised to $1,057 from $850 at Canaccord

William Pickering

Bernstein

$818

Buy

6.52%

Upside

Reiterated

12/01/25

Bernstein Remains a Buy on Regeneron (REGN)

Cory Kasimov

Evercore ISI

$750

Buy

-2.34%

Downside

Reiterated

11/20/25

Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN)

Geoff Meacham

Citi

$700

Buy

-8.85%

Downside

Reiterated

11/19/25

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

11/19/25

Positive Outlook for Regeneron: Buy Rating Supported by Eylea HD Approval and Strong Portfolio

Carter Gould

Cantor Fitzgerald

$740

Buy

-3.64%

Downside

Reiterated

11/19/25

Cantor Fitzgerald Remains a Buy on Regeneron (REGN)

Trung Huynh

UBS

$595→$660

Hold

-14.06%

Downside

Reiterated

11/07/25

Regeneron price target raised to $660 from $595 at UBSRegeneron price target raised to $660 from $595 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month

xxx

Success Rate

14/21 ratings generated profit

Average Return

+1.39%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.39% per trade.

3 Months

xxx

Success Rate

24/40 ratings generated profit

Average Return

+3.73%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +3.73% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

20/25 ratings generated profit

Average Return

+18.98%

reiterated a buy rating 3 months ago

Copying David Risinger's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +18.98% per trade.

2 Years

xxx

Success Rate

20/25 ratings generated profit

Average Return

+20.16%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +20.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 54 Buy Ratings, 16 Hold Ratings, and 2 Sell Ratings. REGN average Analyst price target in the past 3 months is 774.10.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $10.71 with a range of $8.89 to $13.16. The previous quarter’s EPS was $11.83. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.78B with a range of $3.42B to $4.11B. The previous quarter’s sales results were $3.75B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron’s 12-month average price target is 774.10.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron has 0.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron has a consensus rating of Moderate Buy which is based on 16 buy ratings, 6 hold ratings and 1 sell ratings.

What is Regeneron’s price target?

The average price target for Regeneron is 774.10. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1,057.00 ,the lowest forecast is $627.00. The average price target represents 0.80% Increase from the current price of $767.96.

What do analysts say about Regeneron?

Regeneron’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Detailed List of Analyst Forecasts